NEW APPROACHES TO BRAIN TUMOR THERAPY CNS CONSORTIUM

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 名为“脑肿瘤治疗的新方法”的CNS联盟是专门为结合 并集中13个杰出机构的经验、资源和能力(布朗大学、 哥伦比亚大学、埃默里大学、亨利·福特健康科学中心、约翰霍普金斯大学、马萨诸塞州综合医院、 西北大学李·莫菲特癌症中心，阿拉巴马大学，宾夕法尼亚大学 德克萨斯-圣安东尼奥大学、维克森林大学和华盛顿大学)对原发性脑瘤进行研究。这个 该财团的规模已从7家增加到13家。这扩大了财团的承载能力 推出临床试验，拓宽了用于开发新临床试验的实验室研究资源，扩大了 合作、互动的主题是NCI主办的RFA背后的推动力。 NABTT CNS联盟的主要目标是改善成人原发性心脏病的治疗结果。 脑瘤。该联盟是由国家癌症研究所资助的两个全国性的 对有前景的新治疗策略(手术、放疗、化疗和 生物疗法)、给药途径和临床试验设计在原发性恶性肿瘤治疗中的应用 中枢神经系统。参与机构有(1)大量的成人原发脑患者 肿瘤，(2)护理这些患者的多学科临床专家团队，(3)广泛的临床和实验室 资源，(4)数量惊人的持续的高质量、临床相关、同行评审和NIH资助的临床 和实验室脑肿瘤研究项目，(5)国家公认的肿瘤学、药理学、新的 药物开发，I期和II期临床试验，神经外科和神经病理学，(6)广泛的专业知识 生物统计学、数据管理和多机构研究的协调，以及(7)卓越的声誉 在临床护理和研究方面的卓越表现。该财团通过定义明确的和 组织结构运作顺畅，注重临床试验设计、方案制定、质量 控制、研究监测以及数据管理和分析。 NABTT CNS联盟的次要目标是共享人脑肿瘤标本和临床和 实验室数据进行与(1)原发脑肿瘤的基础生物学有关的额外研究，(2) 原发脑肿瘤新疗法的神经药理学，以及(3)改善患者的护理和生活质量 患有原发脑瘤的成年人。 我们的假设是，脑肿瘤患者的治疗进展将源于合理开发的治疗方法。 基于实验室假设驱动的研究。此外，还将开发有效的新疗法 通过控制良好的多机构临床试验最有效。这项工作的主要长期目标是 因此，建议改善成人原发性脑肿瘤的治疗结果。这将是 通过参与有前景的新药物、生物方法、 和治疗中枢神经系统(CNS)原发恶性肿瘤的给药途径 通过中枢神经系统。初发肿瘤状态的正确诊断及治疗效果评价 使用多模式神经成像方法的治疗是这一目标不可或缺的重要部分。传统型 核磁共振对于检测脑部病变极为敏感；然而，它的诊断特异性，如它的能力， 区分肿瘤类型、分级或将肿瘤再生与放射性坏死分开，是有限的。因此，我们有 从研究资源在过去4年中的发展中获益良多，允许获得更多 模式(特别是生理成像技术)在3T更快，我们将在 评估TRDS 1-3中正在设计的有前景的新方法。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The CNS consortium titled "New Approaches To Brain Tumor Therapy (NABTT)" is specifically designed to combine and focus the experience, resources and capabilities of thirteen outstanding institutions (Brown University, Columbia University, Emory University, Henry Ford Health Science Center, Johns Hopkins, Mass General Hospital, Lee Moffitt Cancer Center, Northwestern University, University of Alabama, University of Pennsylvania, University of Texas-San Antonio, Wake Forest University, and Washington University) to bear on primary brain tumors. The size of the consortium has grown from seven to thirteen institutions. This expands the consortium's ability to carry out clinical trials, broadens the laboratory research resources from which to develop new clinical trials, expands the cooperative, interactive theme which is the driving force behind this NCI sponsored RFA. The primary objective of the NABTT CNS Consortium is to improve the therapeutic outcome for adults with primary brain tumors. This consortium is one of two nationwide that is funded by the National Cancer Institute to conduct Phase I and II clinical evaluations of promising new treatment strategies (surgery, radiation, chemotherapy, and biologic therapies), routes of admistration, and clinical trial design in the treatment of primary malignancies of the central nervous system. The participating institutions have (1) a large number of adult patients with primary brain tumors, (2) expert multidisciplinary clinical teams caring for these patients, (3) extensive clinical and laboratory resources, (4) a striking number of ongoing high quality, clinically relevant, peer-reviewed and NIH funded clinical and laboratory brain tumor research projects, (5) nationally recognized expertise in oncology, pharmacology, new drug development, Phase I and II clinical trials, neurosurgery, and neuropathology, (6) extensive expertise in biostatistics, data management, and the coordination of multi-institutional studies, and (7) exceptional reputations for excellence in clinical care and research. The consortium adds to these strengths with a well-defined and smoothly functioning organizational structure, and emphasis on clinical trial design, protocol development, quality control, study monitoring, and data management and analysis. The secondary objective of the NABTT CNS Consortium is to share human brain tumor specimens and clinical and laboratory data to conduct additional research pertaining to (1) the basic biology of primary brain tumors, (2) the neuro-pharmacology of new therapies for primary brain tumors, and (3) improving the care and quality of life of adults with primary brain tumors. Our hypothesis is that therapeutic progress for brain tumor patients will arise from treatments rationally developed based on laboratory hypothesis driven research. Furthermore, that effective new treatments will be developed most efficiently through well controlled multi-institutional clinical trials. The primary long-term objective of this proposal is thus to improve the therapeutic outcome for adults with primary brain tumors. This will be accomplished by participating in Phase I and II clinical evaluations of promising new agents, biologic approaches, and routes of administration in the treatment of primary malignancies of the central nervous system (CNS) through the CNS. The proper diagnosis of tumor status upon initial presentation and the evaluation of the effect of treatment using multi-modality neuroimaging approaches are integral and essential parts of this aim. Conventional MRI is extremely sensitive for the detection of brain lesions; however, its diagnostic specificity, such as its ability to distinguish tumor type, grade, or separate tumor regrowth from radiation necrosis, is limited. As such, we have benefited greatly from the developments in the Research Resource over the past 4 years allowing to acquire more modalities (particularly physiological imaging techniques) more rapidly at 3T, and we will collaborate actively in evaluating the promising new methodologies that are being designed in TRDs 1-3.